Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB070 in Moderate-to-Severe Asthma
NCT07886710Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, randomised, double-blind trial of EB070 in asthma (4 arms). Primary endpoint: Adverse Events at Week 32. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
EB070
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07886710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886710.